Reported 8 months ago
The article discusses the growth prospects of Eli Lilly, despite its high valuation. The company has been experiencing strong growth due to the success of new drugs like Zepbound and Mounjaro. Moreover, there is anticipation for the approval of donanemab, an early Alzheimer's treatment that could potentially become a blockbuster drug. Analysts have been increasing their price targets for Eli Lilly, recognizing the potential of its promising products in generating long-term growth and high earnings. With a market capitalization approaching $1 trillion, Eli Lilly is seen as a strong investment with excellent fundamentals and potential for significant gains in various markets.
Source: YAHOO